R

Royalty Pharma plc
D

RPRX

33.420
USD
0.07
(0.21%)
مغلق
حجم التداول
191,779
الربح لكل سهم
3
العائد الربحي
2.54
P/E
17
حجم السوق
14,481,718,325
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AKBA
    -0.10500
    (-5.53%)
    1.79500 USD
    C
    CRBP
    -0.09000
    (-1.09%)
    8.20000 USD
    E
    ETON
    0.080
    (0.55%)
    14.500 USD
    G
    GLYC
    -0.00930
    (-3.06%)
    0.29490 USD
    K
    KPTI
    -0.00940
    (-1.55%)
    0.59840 USD
    V
    VKTX
    2.480
    (7.85%)
    34.090 USD
    V
    VNDA
    -0.08500
    (-1.89%)
    4.41500 USD
    X
    XNCR
    -0.030
    (-0.19%)
    15.740 USD
    المزيد
الأخبار
المقالات

العنوان: Royalty Pharma plc

القطاع: Healthcare
الصناعة: Biotechnology
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.